These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7240346)

  • 21. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
    Slavik M; Saiers JH
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):62-5. PubMed ID: 6836328
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics of divided-dose ifosfamide.
    Nelson RL; Allen LM; Creaven PJ
    Clin Pharmacol Ther; 1976 Mar; 19(3):365-70. PubMed ID: 1261170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
    Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safe decontamination of cytostatics from the nitrogen mustards family. Part one: cyclophosphamide and ifosfamide.
    Štenglová Netíková IR; Petruželka L; Šťastný M; Štengl V
    Int J Nanomedicine; 2018; 13():7971-7985. PubMed ID: 30538471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of the control of mutagenic metabolites derived from cyclophosphamide and ifosfamide by stimulation of protein kinase A.
    Oesch-Bartlomowicz B; Vogel S; Arens HJ; Oesch F
    Mutat Res; 1990 Oct; 232(2):305-12. PubMed ID: 2170835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide--a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity.
    Pool BL; Bos RP; Niemeyer U; Theuws JL; Schmähl D
    Toxicol Lett; 1988 Apr; 41(1):49-56. PubMed ID: 3128896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of in vitro immunosuppression by hepatocyte-generated cyclophosphamide metabolites and 4-hydroperoxycyclophosphamide.
    Kawabata TT; Chapman MY; Kim DH; Stevens WD; Holsapple MP
    Biochem Pharmacol; 1990 Sep; 40(5):927-35. PubMed ID: 2117927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does acrolein contribute to the cytotoxicity of cyclophosphamide?
    Wrabetz E; Peter G; Hohorst HJ
    J Cancer Res Clin Oncol; 1980; 98(2):119-26. PubMed ID: 7217177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on the human pharmacokinetics of isophosphamide (NSC-109724).
    Allen LM; Creaven PJ; Nelson RL
    Cancer Treat Rep; 1976 Apr; 60(4):451-8. PubMed ID: 1277221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.
    Hansen RJ; Ludeman SM; Paikoff SJ; Pegg AE; Dolan ME
    DNA Repair (Amst); 2007 Aug; 6(8):1145-54. PubMed ID: 17485251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into the clinical pharmacokinetics of trofosfamide.
    Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
    Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ifosfamide clinical pharmacokinetics.
    Wagner T
    Clin Pharmacokinet; 1994 Jun; 26(6):439-56. PubMed ID: 8070218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism and pharmacokinetics of oxazaphosphorines.
    Boddy AV; Yule SM
    Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.
    Mohrmann M; Ansorge S; Schmich U; Schönfeld B; Brandis M
    Pediatr Nephrol; 1994 Apr; 8(2):157-63. PubMed ID: 7517170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
    McNiel NO; Morgan LR
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):490-3. PubMed ID: 7298241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tandem mass spectrometric analysis of cyclophosphamide, ifosfamide and their metabolites.
    Liu Z; Chan KK; Wang JJ
    Rapid Commun Mass Spectrom; 2005; 19(18):2581-90. PubMed ID: 16106352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide.
    Takamoto S; Sakura N; Namera A; Yashiki M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 806(1):59-63. PubMed ID: 15149612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
    Voelcker G; Haeglsperger R
    Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutagenic activity of cyclophosphamide, ifosfamide, and trofosfamide in different genes of escherichia coli and salmonella typhimurium after biotransformation through extracts of rodent liver.
    Ellenberger J; Mohn G
    Arch Toxicol; 1975; 33(3):225-40. PubMed ID: 1096853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.